Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Michael Tisdale

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Living Beings

Anatomy

Chemicals & Drugs

Physiology

Lipolysis

Concepts & Ideas

Body Weight

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
23
Russell, Steven
12
Eley, Helen
11
Wyke, Stacey
10
Todorov, Penio
10
Smith, Helen
9
Fearon, Kenneth
9
Hussey, HJ
6
Khal, Jwan
6
Lorite, Maria-Jose
6
Barber, Matthew
5
Ross, James
4
Sanders, Paul
4
Whitehouse, AS
4
Wigmore, Stephen
3
Thornalley, Paul

Sign-in to see all Coauthors

Publications

TOP 3
Tisdale Michael J
Zinc-alpha2-glycoprotein in cachexia and obesity.
Russell S T; Siren P M A; Siren M J; Tisdale M J
Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1,2,6-triphosphate.
Eley Helen L; McDonald Pria S; Russell Steven T; Tisdale Michael J
Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Michael Tisdale (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Tisdale Michael J
Zinc-alpha2-glycoprotein in cachexia and obesity.
Current opinion in supportive and palliative care 2009;3(4):288-93.
2009: Russell S T; Siren P M A; Siren M J; Tisdale M J
Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1,2,6-triphosphate.
Cancer chemotherapy and pharmacology 2009;64(3):517-27.
2009: Eley Helen L; McDonald Pria S; Russell Steven T; Tisdale Michael J
Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition.
Cancer chemotherapy and pharmacology 2009;63(4):651-9.
2009: Russell Steven T; Rajani Seema; Dhadda Raj S; Tisdale Michael J
Mechanism of induction of muscle protein loss by hyperglycaemia.
Experimental cell research 2009;315(1):16-25.
2008: Eley Helen L; Russell Steven T; Tisdale Michael J
Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by beta-hydroxy-beta-methylbutyrate.
American journal of physiology. Endocrinology and metabolism 2008;295(6):E1409-16.
2008: Eley Helen L; Russell Steven T; Tisdale Michael J
Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate.
American journal of physiology. Endocrinology and metabolism 2008;295(6):E1417-26.
2008: Khal Jwan; Tisdale Michael J
Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid (EPA).
Biochemical and biophysical research communications 2008;375(2):238-40.
2008: Eley H L; Russell S T; Tisdale M J
Role of the dsRNA-dependent protein kinase (PKR) in the attenuation of protein loss from muscle by insulin and insulin-like growth factor-I (IGF-I).
Molecular and cellular biochemistry 2008;313(1-2):63-9.
2008: Russell Steven T; Eley Helen L; Wyke Stacey M; Tisdale Michael J
Involvement of phosphoinositide 3-kinase and Akt in the induction of muscle protein degradation by proteolysis-inducing factor.
The Biochemical journal 2008;409(3):751-9.
2008: Deans D A C; Wigmore S J; Gilmour H; Tisdale M J; Fearon K C H; Ross J A
Reply: Expression of the proteolysis-inducing factor core-peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastrooesophageal malignancy.
British journal of cancer 2008;98(1):243.
2008: Eley H L; Skipworth R J E; Deans D A C; Fearon K C H; Tisdale M J
Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2alpha may signal skeletal muscle atrophy in weight-losing cancer patients.
British journal of cancer 2008;98(2):443-9.
2007: Todorov Penio T; Wyke Stacey M; Tisdale Michael J
Identification and characterization of a membrane receptor for proteolysis-inducing factor on skeletal muscle.
Cancer research 2007;67(23):11419-27.
2007: Eley Helen L; Russell Steven T; Tisdale Michael J
Effect of branched-chain amino acids on muscle atrophy in cancer cachexia.
The Biochemical journal 2007;407(1):113-20.
2007: Eley Helen L; Russell Steven T; Baxter Jeffrey H; Mukerji Pradip; Tisdale Michael J
Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli.
American journal of physiology. Endocrinology and metabolism 2007;293(4):E923-31.
2007: Russell S T; Eley H; Tisdale M J
Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II.
Cellular signalling 2007;19(8):1797-806.
2007: Russell Steven T; Eley Helen; Tisdale Michael J
Mechanism of attenuation of angiotensin-II-induced protein degradation by insulin-like growth factor-I (IGF-I).
Cellular signalling 2007;19(7):1583-95.
2007: Eley H L; Russell S T; Tisdale M J
Attenuation of muscle atrophy in a murine model of cachexia by inhibition of the dsRNA-dependent protein kinase.
British journal of cancer 2007;96(8):1216-22.
2007: Eley Helen L; Tisdale Michael J
Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation.
The Journal of biological chemistry 2007;282(10):7087-97.
2006: Bhogal Ameek S; Lorite Maria L; Tisdale Michael J
Changes in nucleic acid and protein levels in atrophying skeletal muscle in cancer cachexia.
Anticancer research 2006;26(6B):4149-54.
2006: Fearon Kenneth C H; Barber Matthew D; Moses Alastair G; Ahmedzai Sam H; Taylor Gillian S; Tisdale Michael J; Murray Gordon D
Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(21):3401-7.
2006: Russell Steven T; Wyke Stacey M; Tisdale Michael J
Mechanism of induction of muscle protein degradation by angiotensin II.
Cellular signalling 2006;18(7):1087-96.
2006: Wyke S M; Tisdale M J
Induction of protein degradation in skeletal muscle by a phorbol ester involves upregulation of the ubiquitin-proteasome proteolytic pathway.
Life sciences 2006;78(25):2898-910.
2006: Tisdale Michael J
Clinical anticachexia treatments.
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2006;21(2):168-74.
2006: Russell Steven T; Sanders Paul M; Tisdale Michael J
Angiotensin II directly inhibits protein synthesis in murine myotubes.
Cancer letters 2006;231(2):290-4.
2005: Tisdale Michael J
Molecular pathways leading to cancer cachexia.
Physiology (Bethesda, Md.) 2005;20():340-8.
2005: Khal J; Wyke S M; Russell S T; Hine A V; Tisdale M J
Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia.
British journal of cancer 2005;93(7):774-80.
2005: Khal J; Hine A V; Fearon K C H; Dejong C H C; Tisdale M J
Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss.
The international journal of biochemistry & cell biology 2005;37(10):2196-206.
2005: Sanders P M; Russell S T; Tisdale M J
Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia.
British journal of cancer 2005;93(4):425-34.
2005: Russell S T; Tisdale M J
Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia.
Prostaglandins, leukotrienes, and essential fatty acids 2005;72(6):409-14.
2005: Smith Helen J; Khal Jwan; Tisdale Michael J
Downregulation of ubiquitin-dependent protein degradation in murine myotubes during hyperthermia by eicosapentaenoic acid.
Biochemical and biophysical research communications 2005;332(1):83-8.
2005: Tisdale Michael J
The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting.
The journal of supportive oncology 2005;3(3):209-17.
2005: Russell S T; Tisdale M J
The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia.
British journal of cancer 2005;92(5):876-81.
2005: Wyke S M; Tisdale M J
NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle.
British journal of cancer 2005;92(4):711-21.
2005: Chand Anita; Wyke Stacey M; Tisdale Michael J
Effect of cancer cachexia on the activity of tripeptidyl-peptidase II in skeletal muscle.
Cancer letters 2005;218(2):215-22.
2005: Smith Helen J; Mukerji Pradip; Tisdale Michael J
Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss.
Cancer research 2005;65(1):277-83.
2005: Wyke Stacey M; Khal Jwan; Tisdale Michael J
Signalling pathways in the induction of proteasome expression by proteolysis-inducing factor in murine myotubes.
Cellular signalling 2005;17(1):67-75.
2004: Beck S A; Tisdale M J
Effect of cancer cachexia on triacylglycerol/fatty acid substrate cycling in white adipose tissue.
Lipids 2004;39(12):1187-9.
2004: Smith Helen J; Wyke Stacey M; Tisdale Michael J
Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate.
Cancer research 2004;64(23):8731-5.
2004: Wyke S M; Russell S T; Tisdale M J
Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation.
British journal of cancer 2004;91(9):1742-50.
2004: Tisdale M J
Tumor-host interactions.
Journal of cellular biochemistry 2004;93(5):871-7.
2004: Wynter Michael P; Russell Steven T; Tisdale Michael J
Effect of n-3 fatty acids on the antitumour effects of cytotoxic drugs.
In vivo (Athens, Greece) 2004;18(5):543-7.
2004: Lattmann Eric; Kinchington Derek; Dunn Simon; Singh Harjit; Ayuko Washington O; Tisdale Michael J
Cytotoxicity of 3,4-dihalogenated 2(5H)-furanones.
The Journal of pharmacy and pharmacology 2004;56(9):1163-70.
2004: Sanders Paul M; Tisdale Michael J
Effect of zinc-alpha2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue.
Cancer letters 2004;212(1):71-81.
2004: Tisdale Michael J
Cancer cachexia.
Langenbeck's archives of surgery / Deutsche Gesellschaft für Chirurgie 2004;389(4):299-305.
2004: Smith H J; Greenberg N A; Tisdale M J
Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice.
British journal of cancer 2004;91(2):408-12.
2004: Smith H J; Wyke S M; Tisdale M J
Role of protein kinase C and NF-kappaB in proteolysis-inducing factor-induced proteasome expression in C(2)C(12) myotubes.
British journal of cancer 2004;90(9):1850-7.
2004: Zhao Kejun; Wang Yongfeng; Zhao Linxiang; Ji Zhizhong; Li Dan; Tisdale Michael J; Schwalbe Carl H
Synthesis and cytotoxicity of a novel 1-alkylaminomethyl-2,4-diaryl-butadiene-1,3 fragment integrated within cyclohex(pent)enes.
Farmaco (Società chimica italiana : 1989) 2004;59(5):373-9.
2004: Sanders P M; Tisdale M J
Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage.
British journal of cancer 2004;90(6):1274-8.
2004: Russell Steven T; Zimmerman Thomas P; Domin Barbara A; Tisdale Michael J
Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein.
Biochimica et biophysica acta 2004;1636(1):59-68.
2003: Smith H J; Tisdale M J
Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes.
British journal of cancer 2003;89(9):1783-8.
2003: Fearon K C H; Von Meyenfeldt M F; Moses A G W; Van Geenen R; Roy A; Gouma D J; Giacosa A; Van Gossum A; Bauer J; Barber M D; Aaronson N K; Voss A C; Tisdale M J
Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial.
Gut 2003;52(10):1479-86.
2003: Tisdale Michael J
Pathogenesis of cancer cachexia.
The journal of supportive oncology 2003;1(3):159-68.
2003: Lattmann Eric; Ayuko Washington O; Kinchinaton Derek; Langley Christopher A; Singh Harjit; Karimi Leila; Tisdale Michael J
Synthesis and evaluation of 5-arylated 2(5H)-furanones and 2-arylated pyridazin-3(2H)-ones as anti-cancer agents.
The Journal of pharmacy and pharmacology 2003;55(9):1259-65.
2003: Whitehouse A S; Tisdale M J
Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB.
British journal of cancer 2003;89(6):1116-22.
2003: Whitehouse A S; Khal J; Tisdale M J
Induction of protein catabolism in myotubes by 15(S)-hydroxyeicosatetraenoic acid through increased expression of the ubiquitin-proteasome pathway.
British journal of cancer 2003;89(4):737-45.
2003: Simpson Julie; Forrester Rebecca; Tisdale Michael J; Billington David C; Rathbone Daniel L
Effect of catechol derivatives on cell growth and lipoxygenase activity.
Bioorganic & medicinal chemistry letters 2003;13(15):2435-9.
2003: Smith H J; Tisdale M J
Induction of apoptosis by a cachectic-factor in murine myotubes and inhibition by eicosapentaenoic acid.
Apoptosis : an international journal on programmed cell death 2003;8(2):161-9.
2003: Tisdale Michael J
The 'cancer cachectic factor'.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2003;11(2):73-8.
2002: Tisdale Michael J
Cachexia in cancer patients.
Nature reviews. Cancer 2002;2(11):862-71.
2002: Russell S T; Tisdale M J
Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo.
British journal of cancer 2002;87(5):580-4.
2002: Tisdale Michael J
Biochemical mechanisms of cellular catabolism.
Current opinion in clinical nutrition and metabolic care 2002;5(4):401-5.
2002: Russell S T; Hirai K; Tisdale M J
Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor.
British journal of cancer 2002;86(3):424-8.
2001: Islam-Ali B; Khan S; Price S A; Tisdale M J
Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF).
British journal of cancer 2001;85(5):758-63.
2001: Lorite M J; Smith H J; Arnold J A; Morris A; Thompson M G; Tisdale M J
Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF).
British journal of cancer 2001;85(2):297-302.
2001: Whitehouse A S; Tisdale M J
Downregulation of ubiquitin-dependent proteolysis by eicosapentaenoic acid in acute starvation.
Biochemical and biophysical research communications 2001;285(3):598-602.
2001: Islam-Ali B S; Tisdale M J
Effect of a tumour-produced lipid-mobilizing factor on protein synthesis and degradation.
British journal of cancer 2001;84(12):1648-55.
2001: Tisdale M J
Cancer anorexia and cachexia.
Nutrition (Burbank, Los Angeles County, Calif.) 2001;17(5):438-42.
2001: Whitehouse A S; Smith H J; Drake J L; Tisdale M J
Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid.
Cancer research 2001;61(9):3604-9.
2001: Belizário J E; Lorite M J; Tisdale M J
Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia.
British journal of cancer 2001;84(8):1135-40.
2001: Tisdale M J
Loss of skeletal muscle in cancer: biochemical mechanisms.
Frontiers in bioscience : a journal and virtual library 2001;6():D164-74.
2001: Barber M D; Fearon K C; Tisdale M J; McMillan D C; Ross J A
Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia.
Nutrition and cancer 2001;40(2):118-24.
2000: Tisdale M J
Metabolic abnormalities in cachexia and anorexia.
Nutrition (Burbank, Los Angeles County, Calif.) 2000;16(10):1013-4.
2000: Tisdale M J
Biomedicine. Protein loss in cancer cachexia.
Science (New York, N.Y.) 2000;289(5488):2293-4.
2000: Hussey H J; Todorov P T; Field W N; Inagaki N; Tanaka Y; Ishitsuka H; Tisdale M J
Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor.
British journal of cancer 2000;83(1):56-62.
2000: Hussey H J; Tisdale M J
Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model.
International journal of cancer. Journal international du cancer 2000;87(1):95-100.
2000: Wigmore S J; Todorov P T; Barber M D; Ross J A; Tisdale M J; Fearon K C
Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor.
The British journal of surgery 2000;87(1):53-8.
2000: Tisdale M J
Catabolism of skeletal muscle proteins and its reversal in cancer cachexia.
Nestlé Nutrition workshop series. Clinical & performance programme 2000;4():135-43; discussion 144-6.
2000: Wigmore S J; Barber M D; Ross J A; Tisdale M J; Fearon K C
Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer.
Nutrition and cancer 2000;36(2):177-84.
1999: Smith H J; Lorite M J; Tisdale M J
Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid.
Cancer research 1999;59(21):5507-13.
1999: Barber M D; Ross J A; Voss A C; Tisdale M J; Fearon K C
The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer.
British journal of cancer 1999;81(1):80-6.
1999: Todorov P T; Field W N; Tisdale M J
Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361).
British journal of cancer 1999;80(11):1734-7.
1999: Hussey H J; Tisdale M J
Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid.
British journal of cancer 1999;80(8):1231-5.
1999: Khan S; Tisdale M J
Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor.
International journal of cancer. Journal international du cancer 1999;80(3):444-7.
1999: Tisdale M J
Wasting in cancer.
The Journal of nutrition 1999;129(1S Suppl):243S-246S.
1998: Price S A; Tisdale M J
Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid.
Cancer research 1998;58(21):4827-31.
1998: Lorite M J; Thompson M G; Drake J L; Carling G; Tisdale M J
Mechanism of muscle protein degradation induced by a cancer cachectic factor.
British journal of cancer 1998;78(7):850-6.
1998: Hirai K; Hussey H J; Barber M D; Price S A; Tisdale M J
Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients.
Cancer research 1998;58(11):2359-65.
1998: Todorov P T; McDevitt T M; Meyer D J; Ueyama H; Ohkubo I; Tisdale M J
Purification and characterization of a tumor lipid-mobilizing factor.
Cancer research 1998;58(11):2353-8.
1998: Tisdale M J
New cachexic factors.
Current opinion in clinical nutrition and metabolic care 1998;1(3):253-6.
1997: Tisdale M J
Isolation of a novel cancer cachectic factor.
The Proceedings of the Nutrition Society 1997;56(2):777-83.
1997: Todorov P T; Deacon M; Tisdale M J
Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation.
The Journal of biological chemistry 1997;272(19):12279-88.
1997: Tisdale M J
Cancer cachexia: metabolic alterations and clinical manifestations.
Nutrition (Burbank, Los Angeles County, Calif.) 1997;13(1):1-7.
1997: Lorite M J; Cariuk P; Tisdale M J
Induction of muscle protein degradation by a tumour factor.
British journal of cancer 1997;76(8):1035-40.
1997: Cariuk P; Lorite M J; Todorov P T; Field W N; Wigmore S J; Tisdale M J
Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients.
British journal of cancer 1997;76(5):606-13.
1997: Hussey H J; Tisdale M J
Mechanism of the anti-tumour effect of 2,3,5-trimethyl-6-(3-pyridylmethyl) 1,4-benzoquinone (CV-6504).
British journal of cancer 1997;75(6):845-9.
1996: Hussey H J; Tisdale M J
Metabolism and pharmacokinetics of the anti-tumour agent 2,3,5-trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504).
British journal of cancer 1996;74(9):1349-53.
1996: Hussey H J; Tisdale M J
Inhibition of tumour growth by lipoxygenase inhibitors.
British journal of cancer 1996;74(5):683-7.
1996: Hussey H J; Bibby M C; Tisdale M J
Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).
British journal of cancer 1996;73(10):1187-92.
1996: Tisdale M J; McDevitt T M; Todorov P T; Cariuk P
Catabolic factors in cancer cachexia.
In vivo (Athens, Greece) 1996;10(2):131-6.
1996: Todorov P T; McDevitt T M; Cariuk P; Coles B; Deacon M; Tisdale M J
Induction of muscle protein degradation and weight loss by a tumor product.
Cancer research 1996;56(6):1256-61.
1996: Tisdale M J
Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia.
Nutrition (Burbank, Los Angeles County, Calif.) 1996;12(1 Suppl):S31-3.
1995: McDevitt T M; Todorov P T; Beck S A; Khan S H; Tisdale M J
Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans.
Cancer research 1995;55(7):1458-63.
1995: Clark A S; Deans B; Stevens M F; Tisdale M J; Wheelhouse R T; Denny B J; Hartley J A
Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.
Journal of medicinal chemistry 1995;38(9):1493-504.
1994: Hudson E A; Tisdale M J
Comparison of the effectiveness of eicosapentaenoic acid administered as either the free acid or ethyl ester as an anticachectic and antitumour agent.
Prostaglandins, leukotrienes, and essential fatty acids 1994;51(2):141-5.
1994: Hussey H J; Tisdale M J
Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo.
British journal of cancer 1994;70(1):6-10.
1994: Hudson E A; Tisdale M J
Alterations in plasma and tumour levels of fatty acids with weight loss in an experimental cachexia model.
Prostaglandins, leukotrienes, and essential fatty acids 1994;50(5):229-34.
1994: Tisdale M J; Beck S A; Hudson E A
Effects of eicosapentaenoic acid on tumour growth and cachexia in mouse colon cancer.
World review of nutrition and dietetics 1994;76():86-8.
1993: Smith K L; Tisdale M J
Mechanism of muscle protein degradation in cancer cachexia.
British journal of cancer 1993;68(2):314-8.
1993: Hudson E A; Beck S A; Tisdale M J
Kinetics of the inhibition of tumour growth in mice by eicosapentaenoic acid-reversal by linoleic acid.
Biochemical pharmacology 1993;45(11):2189-94.
1993: Tisdale M J
Cancer cachexia.
Anti-cancer drugs 1993;4(2):115-25.
1993: Smith K L; Tisdale M J
Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia.
British journal of cancer 1993;67(4):680-5.
1993: Tisdale M J
Mechanism of lipid mobilization associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein.
Prostaglandins, leukotrienes, and essential fatty acids 1993;48(1):105-9.
1992: McDevitt T M; Tisdale M J
Tumour-associated hypoglycaemia in a murine cachexia model.
British journal of cancer 1992;66(5):815-20.
1992: Mulligan H D; Mahony S M; Ross J A; Tisdale M J
Weight loss in a murine cachexia model is not associated with the cytokines tumour necrosis factor-alpha or interleukin-6.
Cancer letters 1992;65(3):239-43.
1992: Mulligan H D; Beck S A; Tisdale M J
Lipid metabolism in cancer cachexia.
British journal of cancer 1992;66(1):57-61.
1992: Deans B; Tisdale M J
Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide.
Cancer letters 1992;63(2):151-7.
1992: Smith K L; Steven F S; Tisdale M J
Observations on the inhibition of serum and cell surface enzymes by eicosapentaenoic acid.
Journal of enzyme inhibition 1992;6(4):303-15.
1991: Mulligan H D; Tisdale M J
Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo.
British journal of cancer 1991;64(6):1035-8.
1991: Beck S A; Smith K L; Tisdale M J
Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover.
Cancer research 1991;51(22):6089-93.
1991: Mulligan H D; Tisdale M J
Metabolic substrate utilization by tumour and host tissues in cancer cachexia.
The Biochemical journal 1991;277 ( Pt 2)():321-6.
1991: Beck S A; Tisdale M J
Lipid mobilising factors specifically associated with cancer cachexia.
British journal of cancer 1991;63(6):846-50.
1991: Hepburn P A; Margison G P; Tisdale M J
Enzymatic methylation of cytosine in DNA is prevented by adjacent O6-methylguanine residues.
The Journal of biological chemistry 1991;266(13):7985-7.
1991: Mulligan H D; Tisdale M J
Lipogenesis in tumour and host tissues in mice bearing colonic adenocarcinomas.
British journal of cancer 1991;63(5):719-22.
1991: Briddon S; Beck S A; Tisdale M J
Changes in activity of lipoprotein lipase, plasma free fatty acids and triglycerides with weight loss in a cachexia model.
Cancer letters 1991;57(1):49-53.
1991: Hepburn P A; Tisdale M J
Importance of the O6 position of guanine residues in the binding of DNA methylase to DNA.
Biochimica et biophysica acta 1991;1088(3):341-4.
1991: Hepburn P A; Tisdale M J
Antitumour imidazotetrazines--XXIV. Growth suppression by DNA from cells treated with imidazotetrazinones.
Biochemical pharmacology 1991;41(3):339-43.
1991: Tisdale M J; Beck S A
Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid.
Biochemical pharmacology 1991;41(1):103-7.
1990: Beck S A; Mulligan H D; Tisdale M J
Lipolytic factors associated with murine and human cancer cachexia.
Journal of the National Cancer Institute 1990;82(24):1922-6.
1990: Tisdale M J
Newly identified factors that alter host metabolism in cancer cachexia.
Trends in pharmacological sciences 1990;11(12):473-5.
1990: Beck S A; Groundwater P; Barton C; Tisdale M J
Alterations in serum lipolytic activity of cancer patients with response to therapy.
British journal of cancer 1990;62(5):822-5.
1990: Groundwater P; Beck S A; Barton C; Adamson C; Ferrier I N; Tisdale M J
Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients.
British journal of cancer 1990;62(5):816-21.
1990: Beck S A; Tisdale M J
Effect of megestrol acetate on weight loss induced by tumour necrosis factor alpha and a cachexia-inducing tumour (MAC16) in NMRI mice.
British journal of cancer 1990;62(3):420-4.
1990: Tisdale M J; Dhesi J K
Inhibition of weight loss by omega-3 fatty acids in an experimental cachexia model.
Cancer research 1990;50(16):5022-6.
1990: Tisdale M J; Beck S A
Cancer cachexia.
International journal of pancreatology : official journal of the International Association of Pancreatology 1990;7(1-3):141-50.
1990: Mahony S M; Tisdale M J
Metabolic effects of tumour necrosis factor alpha in NMRI mice.
British journal of cancer 1990;61(4):514-9.
1990: Tisdale M J
Metabolic effects in a murine cachexia model.
Biochemical Society transactions 1990;18(1):83-4.
1989: Mahony S M; Tisdale M J
Role of prostaglandins in tumour necrosis factor induced weight loss.
British journal of cancer 1989;60(1):51-5.
1989: Beck S A; Tisdale M J
Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice.
Cancer research 1989;49(14):3800-4.
1989: Mahony S M; Tisdale M J
Reversal of weight loss induced by tumour necrosis factor-alpha.
Cancer letters 1989;45(3):167-72.
1989: Beck S A; Tisdale M J
Effect of insulin on weight loss and tumour growth in a cachexia model.
British journal of cancer 1989;59(5):677-81.
1989: Tisdale M J
Antitumour imidazotetrazines--XVIII. Modification of the level of 5-methylcytosine in DNA by 3-substituted imidazotetrazinones.
Biochemical pharmacology 1989;38(7):1097-101.
1988: Tisdale M J; Brennan R A
A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model.
British journal of cancer 1988;58(5):580-3.
1988: Tisdale M J; Leung Y C
Changes in host liver fatty acid synthase in tumour-bearing mice.
Cancer letters 1988;42(3):231-5.
1988: Mahony S M; Tisdale M J
Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor.
British journal of cancer 1988;58(3):345-9.
1988: Hooper N I; Tisdale M J; Thornalley P J
Modification of the glyoxalase system in human HL60 promyelocytic leukaemia cells during differentiation to neutrophils in vitro.
Biochimica et biophysica acta 1988;966(3):362-9.
1988: Mahony S M; Beck S A; Tisdale M J
Comparison of weight loss induced by recombinant tumour necrosis factor with that produced by a cachexia-inducing tumour.
British journal of cancer 1988;57(4):385-9.
1988: Tisdale M J
Antitumour imidazotetrazines and gene expression.
Acta oncologica (Stockholm, Sweden) 1988;27(5):511-6.
1988: Thornalley P J; Tisdale M J
Inhibition of proliferation of human promyelocytic leukaemia HL60 cells by S-D-lactoylglutathione in vitro.
Leukemia research 1988;12(11-12):897-904.
1987: Beck S A; Tisdale M J
Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host.
Cancer research 1987;47(22):5919-23.
1987: Bull V L; Tisdale M J
Antitumour imidazotetrazines--XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones.
Biochemical pharmacology 1987;36(19):3215-20.
1987: Hooper N I; Tisdale M J; Thornalley P J
Glyoxalase activity during differentiation of human leukaemia cells in vitro.
Leukemia research 1987;11(12):1141-8.

Sign-in to see more